Compare abrdn Income Credit Strategies Fund (ACP) vs Johnson & Johnson (JNJ) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
abrdn Income Credit Strategies Fund vs Johnson & Johnson — how do they compare? abrdn Income Credit Strategies Fund trades at $5.21 (market cap $656.21M), while Johnson & Johnson trades at $266.11 (market cap $643.30B). The key difference: Johnson & Johnson is far larger — about 980.3× abrdn Income Credit Strategies Fund's market cap, and abrdn Income Credit Strategies Fund pays the higher dividend (17.78%). Which is the better fit depends on your goals.
| ACP | JNJ | |
|---|---|---|
Market Cap | $656.21M | $643.30B |
Sector | Financials | Health |
52-Week High | $5.98 | $267.24 |
52-Week Low | $5.01 | $155.17 |
Dividend Yield | 17.78% | 2.01% |
Volume | — | 6,156,228 |
Enterprise Value | — | $676.24B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACP trades at $5.25, down 0.57% today, with a neutral technical signal. The stock shows a low P/B of 0.89 and a high net income margin of 95.51% for 2024, though revenue declined from $79M in 2024 to $42M in 2025. Recent news highlights dividend declarations and a Seeking Alpha downgrade citing distribution sustainability concerns. Cash flow from operations was negative $81.31M in 2024, offset by financing inflows.
Outlook is mixed: valuation appears modest with a P/E near 16, but declining revenue and negative operating cash flow pose risks. The 17% distribution rate faces sustainability questions, while technical indicators suggest limited near-term momentum. Investors should weigh income potential against fundamental weaknesses and high beta exposure.
Johnson & Johnson (JNJ) trades at $267.24, up 1.6% today, near its 52-week high. The stock shows strong profitability with a 21.83% net income margin and 26.42% ROE, though valuation ratios like P/E of 30.05 are elevated. Recent earnings have mostly beaten expectations, with Q1 2026 EPS of $2.70 surpassing estimates. Technical indicators are bullish, with the price above key moving averages and support at $256.
JNJ's outlook is supported by steady revenue growth and a robust dividend, but high valuation and debt-to-asset ratio of 24.06% pose risks. Analyst consensus is bullish with a $260 price target, though near-term performance may hinge on Q2 2026 earnings due July 15. Investors should weigh solid fundamentals against premium pricing and macroeconomic pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About abrdn Income Credit Strategies Fund
abrdn Income Credit Strategies Fund is a diversified, closed-end investment management company. Its primary goal is to generate high current income, with capital appreciation as a secondary objective. The fund mainly invests in debt and loan instruments from issuers across various industries and regions.
Read more on ACP →About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →
